OBI Pharma Showcases Biomarker Innovations at Singapore APAC Summit
Precision Medicine Tools Drive Success in New Drug Development

Biomarkers have become indispensable indicators for precision oncology, providing crucial insights for evaluating drugs, assessing therapeutic activity, guiding patient selection in clinical trials, and determining potential future indications. OBI Pharma (4174.TWO) has been invited to deliver a keynote at the 2024 World Companion Diagnostics & Liquid Biopsy Summit APAC in Singapore on November 13-14. Dr. Michelle Yang, the Director of the Project Management Office at OBI Pharma, will present on the topic "Translating Biomarker Studies from Preclinical to Clinical Development," illustrating how biomarker technology can expedite the drug development process.